| Followers | 16 |
| Posts | 1805 |
| Boards Moderated | 0 |
| Alias Born | 07/21/2013 |
Saturday, June 19, 2021 6:17:19 AM
I think it depends how well you know yourself.
About a year ago my AVXL position was about 10x my normal position size.
I was 61 years old, not wealthy, and this seemed awful risky.
I was uncomfortable and sold half.
I immediately knew it was the right thing to do for me.
Do I now regret this?
No, that would be foolish and playing hindsight games.
For the last year I've enjoyed AVXL's progress stress free.
I would recommend most sell some and bank the money, keep some and enjoy the ride.
If you know you'll beat yourself up if you sell some and the share price continues to rise and you'll beat yourself up if you don't sell some and it tanks, you should get to know yourself better and then act accordingly.
In the interest of full disclosure I did increase my position by 20% @$12 a share a few months ago.
https://mebfaber.com/2013/07/26/just-go-halfsies/
https://seekingalpha.com/article/131980-the-wisdom-of-half-positions
About a year ago my AVXL position was about 10x my normal position size.
I was 61 years old, not wealthy, and this seemed awful risky.
I was uncomfortable and sold half.
I immediately knew it was the right thing to do for me.
Do I now regret this?
No, that would be foolish and playing hindsight games.
For the last year I've enjoyed AVXL's progress stress free.
I would recommend most sell some and bank the money, keep some and enjoy the ride.
If you know you'll beat yourself up if you sell some and the share price continues to rise and you'll beat yourself up if you don't sell some and it tanks, you should get to know yourself better and then act accordingly.
In the interest of full disclosure I did increase my position by 20% @$12 a share a few months ago.
https://mebfaber.com/2013/07/26/just-go-halfsies/
https://seekingalpha.com/article/131980-the-wisdom-of-half-positions
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
